Needle biopsies on autopsy prostates: Sensitivity of cancer detection based on true prevalence

被引:169
作者
Haas, Gabriel P.
Delongchamps, Nicolas Barry
Jones, Richard F.
Chandan, Vishal
Serio, Angel M.
Vickers, Andrew J.
Jumbelic, Mary
Threatte, Gregory
Korets, Rus
Lilja, Hans
de la Roza, Gustavo
机构
[1] State Univ New Yrok Upstate Med Univ, Dept Urol, Syracuse, NY 13210 USA
[2] Onondaga Cty Med Exminer, Syracuse, NY USA
[3] Mem Sloan Kettering Canc Ctr, Dept Epidemiol, New York, NY 10021 USA
[4] Mem Sloan Kettering Canc Ctr, Dept Biostat, New York, NY 10021 USA
[5] Mem Sloan Kettering Canc Ctr, Dept Urol, New York, NY 10021 USA
来源
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE | 2007年 / 99卷 / 19期
关键词
D O I
10.1093/jnci/djm153
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background It is difficult to estimate the diagnostic accuracy of biopsy for prostate cancer because men with negative biopsy do not undergo radical prostatectomy and thus have no confirmation of biopsy findings. Methods We performed 18-core needle biopsies on autopsy prostates from 164 men who had no history of prostate cancer. Six-core biopsies were taken from each of the mid peripheral zone (MPZ), the lateral peripheral zone (LPZ), and the central zone (CZ). We tested associations between age and tumor characteristics and analyzed the sensitivity of biopsies at each site. All statistical tests were two-sided. Results Prostate cancer was present in 47 (29%) prostates. Of the 47 cancers detected, 20 were clinically significant according to histologic criteria. Tumor volume was associated with tumor grade (P =.012) and with age (P<.001). The biopsies from the CZ did not detect any cancer that was not present in biopsies of either the MPZ or LPZ. The sensitivity of the biopsies taken from the MPZ and LPZ together (53%, 95% confidence interval [CII = 38% to 68%) was therefore the same as that of 18-core biopsies and was superior to that of biopsies of the MPZ alone (30%, 95% Cl = 17% to 45%) (P =.003). The sensitivities of biopsies from the MPZ for clinically significant and insignificant cancer were 55% (95% C1 = 32% to 77%) and 11% (95% Cl = 2% to 29%), respectively, compared with 80% (95% C1 = 56% to 94%) and 33% (95% Cl = 17% to 54%) for those from the MPZ and LPZ combined. Conclusions The ability to detect prostate cancer was more related to the biopsy site than to the number of biopsy cores taken. The 12-core biopsies, six cores each from the MPZ and LPZ, were most likely to detect the majority of clinically significant cancers but also detected many insignificant cancers. When the six-core biopsies from the CZ were added, no increase in sensitivity was observed.
引用
收藏
页码:1484 / 1489
页数:6
相关论文
共 28 条
  • [1] Prostate saturation biopsy in the reevaluation of microfocal prostate cancer
    Boccon-Gibod, L. M.
    de Longehamps, N. Barry
    Toublanc, M.
    Boccon-Gibod, L. A.
    Ravery, V.
    [J]. JOURNAL OF UROLOGY, 2006, 176 (03) : 961 - 963
  • [2] Twelve prostate biopsies detect significant cancer volumes (&gt; 0.5 mL)
    Brössner, C
    Bayer, G
    Madersbacher, S
    Kuber, W
    Klingler, C
    Pycha, A
    [J]. BJU INTERNATIONAL, 2000, 85 (06) : 705 - 707
  • [3] Diagnostic value of systematic biopsy methods in the investigation of prostate cancer: A systematic review
    Eichler, K
    Hempel, S
    Wilby, J
    Myers, L
    Bachmann, LM
    Kleijnen, J
    [J]. JOURNAL OF UROLOGY, 2006, 175 (05) : 1605 - 1612
  • [4] The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma
    Epstein, JI
    Allsbrook, WC
    Amin, MB
    Egevad, LL
    Bastacky, S
    Beltrán, AL
    Berner, A
    Billis, A
    Boccon-Gibod, L
    Cheng, L
    Civantos, F
    Cohen, C
    Cohen, MB
    Datta, M
    Davis, C
    Delahunt, B
    Delprado, W
    Eble, JN
    Foster, CS
    Furusato, M
    Gaudin, PB
    Grignon, DJ
    Humphrey, PA
    Iczkowski, KA
    Jones, EC
    Lucia, S
    McCue, PA
    Nazeer, T
    Oliva, E
    Pan, CC
    Pizov, G
    Reuter, V
    Samaratunga, H
    Sebo, T
    Sesterhenn, I
    Shevchuk, M
    Srigley, JR
    Suzigan, S
    Takahashi, H
    Tamboli, P
    Tan, PH
    Têtu, B
    Tickoo, S
    Tomaszewski, JE
    Troncoso, P
    Tsuzuki, T
    True, LD
    van der Kwast, T
    Wheeler, TM
    Wojno, KJ
    [J]. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2005, 29 (09) : 1228 - 1242
  • [5] PATHOLOGICAL AND CLINICAL FINDINGS TO PREDICT TUMOR EXTENT OF NONPALPABLE (STAGE-T1C) PROSTATE-CANCER
    EPSTEIN, JI
    WALSH, PC
    CARMICHAEL, M
    BRENDLER, CB
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 271 (05): : 368 - 374
  • [6] Evidence to support a continued stage migration and decrease in prostate cancer specific mortality
    Galper, SL
    Chen, MH
    Catalona, WJ
    Roehl, KA
    Richie, JP
    D'Amico, AV
    [J]. JOURNAL OF UROLOGY, 2006, 175 (03) : 907 - 912
  • [7] Prevalence and characteristics of screen-detected prostate carcinomas at low prostate-specific antigen levels:: aggressive or insignificant?
    Gosselaar, C
    Roobol, MJ
    Schröder, FH
    [J]. BJU INTERNATIONAL, 2005, 95 (02) : 231 - 237
  • [8] Greene FL., 2002, AJCC CANC STAGING HD, V6th
  • [9] Immunohistochemical stains for p63 and α-methylacyl-CoA racemase, versus a cocktail comprising both, in the diagnosis of prostatic carcinoma -: A comparison of the immunohistochemical staining of 430 foci in radical prostatectomy and needle biopsy tissues
    Hameed, O
    Sublett, J
    Humphrey, PA
    [J]. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2005, 29 (05) : 579 - 587
  • [10] What is 'insignificant' prostate carcinoma?
    Klein, EA
    [J]. CANCER, 2004, 101 (09) : 1923 - 1925